FibroGen, Inc. (NASDAQ:FGEN) Not Doing Enough For Some Investors As Its Shares Slump 27%
FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts
Q3 Pharma and Biotech Layoffs in Charts: More Than 1000 Each in July and August
FibroGen Cuts Costs by Terminating San Francisco Lease Early
Express News | FibroGen Inc: Agrees to $10 Million Settlement Amount
Express News | FibroGen Inc: Modifies Lease to Expire December 2024
Express News | FibroGen Inc: Enters Lease Termination Agreement for Premises Located at 409 Illinois Street
FibroGen Announces Board Member Resignations and Committee Appointments
Executive Reshuffles: HON, CIEN, RNG and ASAN Companies in Focus
FibroGen Terminates CFO Juan Graham, Chief Medical Officer Deyaa Adib
FibroGen CFO, CMO to Leave Company by Year's End
Express News | FibroGen Inc: Juan Graham, Chief Financial Officer Planned Departure Date Is December 15, 2024
FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Investors Don't See Light At End Of FibroGen, Inc.'s (NASDAQ:FGEN) Tunnel And Push Stock Down 64%
FibroGen, Inc. (NASDAQ:FGEN) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
FibroGen Said Tuesday It Would Cut About 75% of U.S. Workforce
Express News | FibroGen Inc: Estimates Non-Recurring Charges of $16-18 Million for Restructuring
Express News | FibroGen : Plan to Reduce U.S. Workforce by Approximately 75%, 127 Employees Affected
Express News | FibroGen : Initiates Restructuring Plan After Negative Pamrevlumab Clinical Trial Data
FibroGen Inc.: Sell Rating Maintained Amid Uncertainties and Limited Upside Potential